Rucaparib

Rucaparib is a targeted therapy medication, specifically an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme family. This medication is primarily used for the treatment of advanced ovarian, breast, and prostate cancers. Rucaparib selectively targets and inhibits the PARP enzyme, thereby preventing the repair of DNA damage and causing cancer cell death.
The medication is primarily prescribed for patients with BRCA1/2 mutated cancers, as well as those with HER2 negative metastatic breast cancer. Additionally, it may be used for patients who have experienced disease progression after receiving previous lines of chemotherapy. Rucaparib has demonstrated efficacy in improving progression-free survival and overall survival in these patient populations.
Rucaparib is available as a capsule formulation, to be taken orally. The recommended dose is 600 mg, taken twice daily, with or without food. It is crucial for patients to follow the prescribed dosage and schedule, as well as to maintain regular follow-up appointments with their healthcare provider to monitor treatment effectiveness and to address any potential side effects.
As with any medication, there may be potential side effects associated with the use of rucaparib. These may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation; hematological issues like anemia, thrombocytopenia, and leukopenia; and fatigue or malaise. Additionally, there is a risk of myelodysplastic syndrome and acute myeloid leukemia with long-term use of rucaparib. Patients should discuss these potential side effects with their healthcare provider and report any adverse reactions promptly.